Winton Group LTD Altimmune, Inc. Transaction History

Winton Group LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$8.69 - $12.48 $136,876 - $196,572	-15,751 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$8.43 - $16.81 $132,780 - $264,774	15,751 New	15,751 $178,000
Q1 2021 Jul 21, 2021	SELL	$12.71 - $24.31 $216,133 - $413,391	-17,005 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$7.84 - $14.22 $459,698 - $833,789	-58,635 Reduced 77.52%	17,005 $192,000
Q3 2020 Oct 30, 2020	SELL	$9.93 - $33.26 $604,369 - $2.02 Million	-60,863 Reduced 44.59%	75,640 $998,000
Q2 2020 Aug 05, 2020	BUY	$2.9 - $10.71 $122,858 - $453,729	42,365 Added 45.0%	136,503 $1.46 Million
Q1 2020 May 11, 2020	SELL	$1.69 - $3.8 $6,322 - $14,215	-3,741 Reduced 3.82%	94,138 $302,000
Q4 2019 Feb 13, 2020	BUY	$1.53 - $2.15 $68,384 - $96,096	44,696 Added 84.04%	97,879 $185,000
Q3 2019 Nov 08, 2019	BUY	$1.95 - $2.66 $103,706 - $141,466	53,183 New	53,183 $104,000

186

39.4M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $329M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.